In a surprise approval, FDA green-lights Incyte's PD-1 inhibitor to treat rare cancer type

Sometimes, the second time is the charm. After a 2021 complete response letter from the FDA for approval in a different indication, the agency has now green-lit Incyte’s intravenous drug, Zynyz. The drug got the go-ahead through the FDA’s accelerated approval pathway for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).